Zacks Investment Research on MSN7m
Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.10 per share a year ago. These figures are ...
Zacks Investment Research on MSN21m
Sociedad Quimica's Earnings Miss Estimates in Q4, Revenues Beat
Sociedad Quimica y Minera de Chile S.A. SQM logged earnings of 42 cents per share in fourth-quarter 2024, down from 71 cents ...